The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ABC-12: Exploring the microbiome in patients (pts) with advanced biliary tract cancer (BTC) in a first-line study of durvalumab in combination with cisplatin/gemcitabine (cis/gem).
 
Mairead Geraldine McNamara
Honoraria - Advanced Accelerator Applications (Inst); Novartis
Consulting or Advisory Role - AstraZeneca (Inst); Incyte; Ipsen; Shire; Sirtex Medical
Speakers' Bureau - Nucana
Research Funding - Ipsen; Nucana; SERVIER
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Novartis
 
Hayley Timmins
No Relationships to Disclose
 
Ashley Osborne
No Relationships to Disclose
 
Rebecca Cox
No Relationships to Disclose
 
Harpreet Singh Wasan
Honoraria - Array BioPharma; Celgene; ERYTECH Pharma; Incyte; Merck KGaA; Roche/Genentech; Servier; Sirtex Medical; Zymeworks
Consulting or Advisory Role - Bayer; ERYTECH Pharma; Incyte; Pfizer; Pierre Fabre; Roche Pharma AG; Shire; Sirtex medical
Speakers' Bureau - Celgene; Incyte; Merck KGaA; SERVIER; Sirtex Medical
Research Funding - Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Sirtex Medical (Inst)
Expert Testimony - Oncosil
 
Pippa Corrie
No Relationships to Disclose
 
Roopinder Gillmore
No Relationships to Disclose
 
Shivan Sivakumar
No Relationships to Disclose
 
Yuk Ting Ma
Honoraria - Boston Scientific
Consulting or Advisory Role - AstraZeneca/MedImmune; Eisai; Faron Pharmaceuticals; Ipsen; Roche
Research Funding - AstraZeneca/Merck (Inst); Eisai (Inst); Faron Pharmaceuticals (Inst); MINA THERAPEUTICS (Inst)
 
Olusola Olusesan Faluyi
No Relationships to Disclose
 
Arvind Arora
No Relationships to Disclose
 
Seema Arif
No Relationships to Disclose
 
Jo Canham
No Relationships to Disclose
 
Chris Hurt
No Relationships to Disclose
 
Richard Hubner
No Relationships to Disclose
 
John A Bridgewater
Honoraria - Incyte; SERVIER
Consulting or Advisory Role - AstraZeneca; Basilea; Bayer; Incyte; Merck Serono; Merck Serono; Roche; SERVIER; Taiho Oncology
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene
Research Funding - Amgen; Incyte (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb/Medarex; Merck Serono; MSD Oncology; SERVIER
 
Richard Adams
Honoraria - Amgen; AstraZeneca; Bayer; SERVIER
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; SERVIER
Speakers' Bureau - Merck Serono
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; SERVIER
 
Juan W. Valle
Consulting or Advisory Role - Aptitude Health; AstraZeneca; Autem Medical; Baxter; Boehringer Ingelheim; Cantargia AB; Debiopharm Group; Genoscience Pharma; Hutchison MediPharma; Imaging Equipment Limited; Incyte; Ipsen; Keocyt; Medivir; Merck; Mundipharma; Novartis; Nucana; PCI Biotech; Pfizer; Pieris Pharmaceuticals; QED Therapeutics; SERVIER; Sirtex Medical; Taiho Oncology; Wren Laboratories; Zymeworks
Speakers' Bureau - Delcath Systems; Imaging Equipment Limited; Incyte; Ipsen; Mylan; Novartis; Nucana; SERVIER
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Lilly; Nucana; Roche